Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion
Ezekowitz, Michael D., Cappato, Riccardo, Klein, Allan L., Camm, A. John, Ma, Chang-Sheng, Le Heuzey, Jean-Yves, Talajic, Mario, Scanavacca, Maurício I., Vardas, Panos E., Kirchhof, Paulus, Hohnloser,Volume:
167
Language:
english
Journal:
American Heart Journal
DOI:
10.1016/j.ahj.2013.12.024
Date:
May, 2014
File:
PDF, 196 KB
english, 2014